Results 131 to 140 of about 81,009,517 (308)

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic Hepatitis C virus infection in a European cohort: A cross-sectional study [PDF]

, 2011
Background To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-
Hellard, M, Powell, Elizabeth, Ahlenstiel, G., Smedile, Antonina, Bassendine, Margaret, Hammond, E., O'Connor, Kate S, Armstrong, Nicola J, Stewart, Graeme J, Müller Tobias, Silvana Gaudieri, Mallal Simon, Armstrong Nicola J., Powell Elizabeth, Graeme J Stewart, Bassendine, M, Abate, ML, Jacob Nattermann, Irving, WL, Ahlenstiel, G, Simon Mallal, Negro, F, Stewart, Graeme J., Suppiah, Vijayaprakash, Matthews, G, Suppiah Vijayaprakash, Gaudieri Silvana, Bochud Pierre-Yves, null null, Nattermann, J, Vijayaprakash Suppiah, Hammond, Emma, Graeme J. Stewart, Hellard Margaret, Bochud, P-Y, Mallal, S., Negro, F., Ahlenstiel, Golo (R18999), O'Connor, KS, Smedile, A, Booth, DR, Powell, E, George Jacob, Gaudieri, S., Negro Francesco, Pierre-Yves Bochud, Irving, W.L., David Dunn, Abate, Maria L., Dore Gregory J., Hellard, M., International Hepatitis C Genetics Consortium (IHCGC), Spengler, U., William L Irving, Dunn David, David Sheridan, Riordan Stephen, Berg Thomas, Dunn, D.S., Stewart Graeme J., Mathews, Gail, Weltman, Martin, Ulrich Spengler, Nattermann Jacob, Mallai, Simon, Dunn, D, Francesco Negro, Berg, Thomas, for the International Hepatitis C Genetics Consortium (IHCGC), Gregory J. Dore, Sheridan, D, Abate Maria Lorena, Jacob George, Nicola J Armstrong, Matthews Gail, Mallal, S, Matthews, Gail, Booth, David R, Dore, G.J., Müller, T., Kate S O'Connor, Armstrong, Nicola J., Dore, Gregory J, Gail Matthews, Spengler Ulrich, Müller, T, Booth, David R., Berg, T., Irving, William L., Spengler, U, Booth, D.R., Spengler, Ulrich, Suppiah, V, Powell, E., Martin Weltman, Emma Hammond, Dunn, David, Thomas Berg, Suppiah, Vijay, Matthews, G., Abate, Maria Lorena, Bassendine, M., Berg, T, Riordan, Stephen, Hammond, E, Muller, Tobias, Ahlenstiel, Golo, Nattermann, J., Sheridan David, Smedile Antonina, Kate S. O'Connor, Mallal, Simon, Sheridan, D., Hammond Emma, David R. Booth, Irving William L., Stewart, GJ, Maria Lorena Abate, O'Connor, Kate S., Antonina Smedile, Golo Ahlenstiel, Armstrong, N.J., Margaret Hellard, Dore, GJ, O'Connor Kate S., Gaudieri, S, Hellard, Margaret, David R Booth, Weltman Martin, Riordan, S, Irving, William L, Margaret Bassendine, Tobias Müller, Armstrong, NJ, Weltman, M., Bassendine Margaret, Booth David R., Elizabeth Powell, Smedile, A., William L. Irving, Dore, Gregory J., Stephen Riordan, Weltman, M, Sheridan, David, Negro, Francesco, Bochud, PY, Riordan, S., Bochud, Pierre-Yves, Gregory J Dore, O'Connor, K.S., George, J, Nicola J. Armstrong, Suppiah, V., Stewart, G.J., Ahlenstiel Golo, George, J., George, Jacob, Nattermann, Jacob, Abate, M.L., Gaudieri, Silvana   +159 more
core   +1 more source

Single‐cell analysis of tumor microenvironment and cell adhesion reveals that interleukin‐1 beta promotes cancer cell proliferation in breast cancer

Animal Models and Experimental Medicine
Background Triple‐negative breast cancer (TNBC), which is so called because of the lack of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) receptors on the cancer cells, accounts for 10%–15% of ...
Wenyan Wang, Gehong Dong, Ziguo Yang, Shaoxiang Li, Jia Li, Lin Wang, Qiang Zhu, Yuchen Wang   +7 more
doaj   +1 more source

Methotrexate associated to lipid core nanoparticles improves cardiac allograft vasculopathy and the inflammatory profile in a rabbit heart graft model

Brazilian Journal of Medical and Biological Research, 2017
Coronary allograft vasculopathy is an inflammatory-proliferative process that compromises the long-term success of heart transplantation and has no effective treatment.
A.I. Fiorelli, D.D. Lourenço-Filho, E.R. Tavares, P.O. Carvalho, A.F. Marques, P.S. Gutierrez, R.C. Maranhão, N.A.G. Stolf   +7 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Expression of the IL-10 receptor on human monocytes is moderately suppressed by glucocorticoids

, 2002
Chemicals/CAS: Dexamethasone, 50-02-2; Receptors, Interleukin; Receptors, Interleukin ...
Nagelkerken, L., Visser, J.
core  

Interleukin-18 [PDF]

, 2003
Interleukin-18 (IL-18), a recently described member of the IL-1 cytokine superfamily, is now recognized as an important regulator of innate and acquired immune responses.
McInnes, I.B., Robertson, S.E., Gracie, J.A.   +2 more
core   +1 more source

The impact of long-term exposure to space environment on adult mammalian organisms: a study on mouse thyroid and testis.

PLoS ONE, 2012
Hormonal changes in humans during spaceflight have been demonstrated but the underlying mechanisms are still unknown. To clarify this point thyroid and testis/epididymis, both regulated by anterior pituitary gland, have been analyzed on long-term space ...
Maria Angela Masini, Elisabetta Albi, Cristina Barmo, Tommaso Bonfiglio, Lara Bruni, Laura Canesi, Samuela Cataldi, Francesco Curcio, Marta D'Amora, Ivana Ferri, Katsumasa Goto, Fuminori Kawano, Remo Lazzarini, Elisabetta Loreti, Naoya Nakai, Takashi Ohira, Yoshinobu Ohira, Silvio Palmero, Paola Prato, Franco Ricci, Linda Scarabelli, Tsubasa Shibaguchi, Renza Spelat, Felice Strollo, Francesco Saverio Ambesi-Impiombato   +24 more
doaj   +1 more source

Dysregulated Cholesterol Metabolism, Chronic Inflammation, and Disability in Severe Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Dysregulated lipid metabolism, which can affect remyelination and neural repair, has not been extensively investigated in progressive multiple sclerosis (PMS). The goal was to examine whether dysregulated cholesterol metabolism was associated with disability in PMS. Methods The study sample comprised 53 Severe PMS patients (Expanded
Taylor R. Wicks, Mujeeb Shittu, Anna Wolska, Diala Ghazal, Bianca Weinstock‐Guttman, Alexander Burnham, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +8 more
wiley   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

Arthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho, Shangyi Gao, Daniel Pereira, Richard J. Cook, Dafna D. Gladman   +4 more
wiley   +1 more source